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Efficacy and safety of local lysozyme treatment in patients 
with oral mucositis after chemotherapy and radiotherapy
This observational clinical study was composed of two 
substudies: a non-comparative one (n = 166), testing only 
lysozyme-based compounds (LBCs), and a comparative 
substudy (n = 275), testing both LBCs and bicarbonate-
based local compounds (BBCs) on the healing of oral mu-
cositis during radio- or chemotherapy. The density of ul-
cerations has decreased significantly after the treatment 
with lysozyme in both substudies. The density of ulcer-
ations in the radiotherapy group was lower in patients 
treated with LBCs compared to patients treated with 
BBCs (p < 0.001). In the chemotherapy group, reduction of 
ulceration density was similar with both LBCs and BBCs. 
The LBCs reduced pain intensity during the intake of 
solid food and speech more than BBCs in both patient co-
horts (p < 0.05). In the radiotherapy cohort, pain intensity 
when consuming liquid foods was reduced more with 
LBCs than with BBCs (p < 0.05). No adverse events were 
recorded. This study demonstrates the advantages of 
treating oral mucositis during radiotherapy or chemo-
therapy with LBCs. 
Keywords: oral mucositis, treatment efficacy, radiotherapy, 
chemotherapy, topical, lysozyme
Oral mucositis is an inflammation of gastrointestinal mucosa accompanying radiother-
apy or chemotherapy, most often localized to oral or oropharyngeal mucosa (1) (2). The in-
cidence of oral mucositis depends on the type of therapy (1). It usually appears in all patients 
between the 7th and the 14th day after the onset of radiotherapy in head and neck cancer 
patients, whereas 30 to 75 % of patients on chemotherapy have oral ulcers (2) (3). Cytostatic 
drugs most frequently associated with oral mucositis are antimetabolites, such as 5-fluoro-
uracil, methotrexate and purine antagonists, but this adverse effect is also encountered in 
patients who take anthracycline antitumor antibiotics (e.g. doxorubicin) or taxanes (e.g. pa-
clitaxel and docetaxel) (1). It is believed that oral mucositis is a consequence of direct toxic 
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Patients with oral mucositis experience strong pain and difficulties when swallowing 
along with impaired feeding, speech, and general functioning, since keeping oral hygiene 
becomes a difficult task (2–4). Diagnosis of oral mucositis is based on the patient’s history 
and clinical examination. A number of questionnaires for the assessment of oral mucositis 
were developed, but one the most frequently used in the practice is the Oral Mucositis 
 Assessment Scale (OMAS) (5). Oral mucositis is the leading cause of dose decrease or pre-
mature termination of radio- or chemotherapy (decreasing chances of survival), and is 
accompanied with increased utilization of analgesics and antibiotics, prolonged hospi-
taliza tion and increased treatment costs (6, 7). It is also considered to be a socio-economic 
problem since the quality of the patient’s life is severely deteriorated. The quality of life in 
patients with oral mucositis could be assessed by Patient-Reported Oral Mucositis Symptoms 
(PROMS) scale (8).
The goals of oral mucositis treatment are pain control, healing of ulcers, mucose re-
covery, and the prevention of secondary infection. Clinicians still do not agree about the 
optimal treatment protocol for oral mucositis. Currently available therapeutic options are 
focused on palliative measures including the control of pain, feeding support and keeping 
oral hygiene. The therapy mostly involves oral antiseptics, corticosteroids for local use and 
chamomile tea wash-ups. Additional drugs, which may be used for local treatment of oral 
mucositis, are oral antiseptics, antibacterial, antifungal and antiviral drugs, cytoprotective 
drugs, mucosa-protecting agents and drugs which stimulate regeneration of damaged mu-
cosa (7). There are several advanced therapeutic options in the clinical development phase: 
cryotherapy, administration of growth factors, anti-inflammatory drugs, antioxidants and 
low-voltage laser therapy (9). Although the efficacy of local preparations containing lyso-
zyme has been proved in the treatment of acute inflammatory diseases of the mouth and 
throat including recurrent aphthous ulcers, they were never tested on oral mucositis after 
radio- or chemotherapy (10). Lysozyme is present in human saliva and protects oral mu-
cosa by killing bacteria through the hydrolysis of cell wall peptidoglycan matrix. It has 
also proven regenerative effects, has an immunomodulatory role and contributes to the 
resolution of inflammation at mucosal sites (11).
The aim of our study was to compare the efficacy and safety of oral lysozyme-based 
compounds and bicarbonate-based pharmaceutical compounds when used for the treat-
ment of oral mucositis during radio- and chemotherapy.
EXPERIMENTAL
Study design and patients
Our observational study was composed of two prospective cohort substudies: in the 
first substudy all patients with oral mucositis after radio- or chemotherapy (179 enrolled, 
166 completed the study) were treated with lysozyme-based compounds for local admini-
stration, while the other substudy was comparative: the patients with oral mucositis after 
radio- or chemotherapy (292 enrolled, 275 completed the study) were treated either with 
the lysozyme-based compounds for local use, or with bicarbonate-based pharmaceutical 
compounds for local administration. The study was approved by the Drug Agency of 
Bosnia and Herzegovina and performed in accordance with ethical principles for medical 
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research involving human subjects (Declaration of Helsinki). The study subjects were en-
rolled only after signing the informed consent for participation in the study.
The inclusion criteria were age over 18, diagnosis of any type of cancer, currently 
 receiving one cycle of radio- or chemotherapy treatment course and diagnosis of oral 
 mucositis. The exclusion criteria were pregnancy, premature termination of radio- or 
 chemotherapy, incomplete follow-up, severe pain treated by systemic analgesics and 
 severe symptoms completely precluding both solid and liquid food intake.
Study treatments and outcomes
In the first, non-comparative study (n = 166), the lysozyme-based compound was admini-
stered from the first day of radio- or chemotherapy; for the first 7 days. 6–8 compressed 
lozenges of Lysobact® (20 mg of lysozyme + 10 mg of pyridoxine, Bosnalijek d.d.,  Bosnia 
& Herzegovina, OTC preparation) were given daily, and then for the next 14 days Lysobact 
COMPLETE Spray® (lysozyme hydrochloride, cetylpyridinium chloride, and pyridoxine, 
(20 + 1.5+ 0.5) mg mL–1, Bosnalijek d.d., OTC preparation) was administered by the patients 
themselves 3–6 times daily. During the final 7 days of the 28-days study period, the patients 
were again using 6–8 compressed lozenges of Lysobact® daily. The two dosage forms were 
used interchangeably in order to avoid bias from the various capability of patients to self-
-administer the spray properly. 
Outcomes of the first substudy were measured on the 1st, 7th, 21st and 28th day. The 
primary outcome was the number of oral ulcers. Secondary outcomes were quality of life 
(assessed by the PROMS scale) and frequency of adverse events (primarily of the adverse 
effects listed in Summaries of the study products’ characteristics, but also of any serious 
and unsuspected adverse event observed by the study investigators or reported to them 
by the study participants).
In the second, comparative substudy, there were two patient cohorts: the first cohort 
included chemotherapy patients (n = 151) and the second radiotherapy patients (n = 124). 
Within the cohort of chemotherapy patients 82 or 54 % were treated with local administra-
tion of lysozyme-based compounds (from the day one of radio- or chemotherapy; for the 
first 7 days 6-8 compressed lozenges of Lysobact® daily, and then for the next 14 days Ly-
sobact COMPLETE Spray® 3–6 times daily), while the rest were treated by bicarbo nate-
based pharmaceutical compounds; patients from the radiotherapy cohort were also treated 
either by lysozyme-based (n = 66 or 53 % for the first 7 days 6–8 compressed  lozenges of 
Lysobact® daily, and then for the next 14 days Lysobact COMPLETE Spray® 3–6 times 
daily)), or by bicarbonate-based (n = 58 or 47 %) pharmaceutical compounds. The bicarbon-
ate-based pharmaceutical preparations were prepared in various community pharmacies, 
with variable strength and content; majority contained only sodium chloride and sodium 
bicarbonate, while in some hexetidine, nystatin, methylprednisolone, doxy cycline, vitamin 
C or vitamin D were added (the most frequently used sodium bicarbonate solutions were 
1–3 %, m/m).
Outcomes of the second substudy were measured on the 1st, 7th and 21st day. The 
primary outcome was the number of oral ulcers. The secondary outcome was the fre-
quency of adverse events.
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Statistics
The data are presented as mean ± standard deviation and as median and interquartile 
range. Normality of the data distribution was checked by the Kolmogorov-Smirnov test. 
The significant differences in scale variables between two study groups were tested by 
Student’s t-test and differences in scale variables for repeated measures were tested by 
Students paired test. The differences categorical variables were tested by Chi-square test 
or McNemar test for paired categorical data. All calculations were performed by Statistical 
Package for Social Sciences (SPSS) software, version 23.0 for Windows.
RESULTS AND DISCUSSION
In total 166 patients were enrolled in the first, non-comparative substudy (not compar-
ing different treatments): 92 patients were receiving chemotherapy and 74 radiotherapy. 
All patients were treated with lysozyme-based compounds. The average age of patients on 
chemotherapy was 60.5 ± 9.8 years, and of patients on radiotherapy 60.7 ± 12.3 years; the 
difference was not significant (p = 0.94). Among the patients undergoing chemotherapy, 
there were 48 (52.2 %) men and 44 (47.8 %) women, whereas in the radiotherapy subgroup 
there were 26 (35.1 %) men and 48 (64.9 %) women (p = 0.04). 
The percentage of patients on chemotherapy with ulcerations in various parts of the 
oral cavity significantly decreased during the follow-up, as shown in Table I.
The percentage of patients with head or neck cancer on radiotherapy with ulcerations 
in various parts of the oral cavity significantly decreased during the treatment with lyso-
zyme-based compounds. However, lysozyme treatment did not reduce the number of patients 
with upper and lower lip ulcerations (Table II). 
Patients on both chemotherapy and radiotherapy experienced a significant improve-
ment in the quality of life. 
Table I. Percent of patients on chemotherapy (n = 92) with ulcerations in various parts of the oral cavity 
during the treatment with lysozyme-based compounds
The region of the oral 
cavity
7 days after onset of 
the therapy
21 days after onset 
of the therapy
28 days after onset 
of the therapy p-value
a
Upper lip 20 (21.7 %) 5 (5.4 %) 1 (1.1 %) < 0.001
Lower lip 31 (33.7 %) 12 (13.1 %) 4 (4.3 %) < 0.001
Right cheek 31 (33,7 %) 14 (15,2 %) 5 (5.4 %) < 0.001
Left cheek 25 (27.2 %) 14 (15.2 %) 6 (6.5 %) < 0.001
Tongue (dorsal side) 48 (52.2 %) 32 (34.8 %) 14 (15.2 %) < 0.001
Sublingval area 34 (37.0 %) 27 (29.3 %) 5 (5.4 %) < 0.001
Soft palate 21 (22.8 %) 13 (14.1 %) 7 (7.6 %) 0.003
Hard palate 20 (21.7 %) 9 (9.8 %) 1 (1.1 %) < 0.001
a Differences in ulceration occurrence between day 7 and 28 after therapy was calculated using McNemar test.
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Patients on chemotherapy had significant reductions on the pain intensity scale 
(PROMS is a 10-item visual analogue scale the with a maximum score of 100, which mea-
sures symptoms of oral mucositis that affect the quality of life) and scored one unit lower at 
each visit during the therapy with lysozyme. Pain intensity score decreased for one unit from 
the second to third visit (3.0 (3.0–3.0) vs. 2.0 (2.0–3.0); Z =  –7.08; p < 0.001), and decreased an 
additional unit from the third to fourth visit (2.0 (2.0–3.0) vs. 1.0 (1.0–2.0); Z =  –6.7; p < 0.001). 
Therefore, the mean pain intensity score decreased from 3.0 to 1.0, and the highest drop 
was observed between the second and fourth visit (Z = –7.8; p < 0.001). Radiotherapy 
 patients also experienced a decrease in pain intensity score during the therapy with 
 lysozyme-based compounds, from 2.0 (2.0–3.0) to 1.0 (1.0–2.0) (Z = –4.7; p < 0.001) between 
the third and fourth visit, while the decrease was not significant between the second and 
third visit (Z = –1.1; p = 0.26). The trend of improving the quality of life of chemotherapy 
patients was observed in all other domains of the PROMS scale, especially in regard to the 
quality of speech and intake of solid food, but without a statistical significance (results not 
shown for the sake of clarity and brevity). Adverse treatment effects were not observed in 
both subgroups of patients. 
The second, comparative substudy included 275 patients, 151 of them underwent chemo-
therapy, and 124 received radiotherapy. 
Within the radiotherapy group, 66 patients (53 %) were treated with lysozyme-based 
compounds, and 58 patients (47 %) were using bicarbonate-based pharmaceutical compounds. 
There was no significant difference in the mean age between treatment groups (63.0 ± 9.2 
vs. 65.6 ± 10.0 years respectively, p = 0.13). Out of 66 patients treated with lysozyme-based 
compounds, 78.8 % were male and 21.2 % were female, while in the bicarbonate-based 
treatment group there were 65.0 % male and 35.0 % female and no significant difference in 
gender distribution between groups was observed (X2 = 2.9; p = 0.11).
Within the cohort of chemotherapy patients, 82 or 54 % were treated with local admini-
stration of lysozyme-based compounds, whereas 69 (46 %) were treated with bicarbonate-
Table II. Percent of patients on radiotherapy (n = 74) with ulcerations in various parts of the oral cavity after 
treatment with lysozyme-based compounds
The region of the oral 
cavity
7 days after onset of 
the therapy
21 days after onset 
of the therapy
28 days after onset 
of the therapy p-value
a
Upper lip 13 (17.6 %) 15 (20.3 %) 11 (14.9 %) 0.680
Lower lip 14 (19.0 % %) 14 (19.0 %) 10 (13.5 %) 0.290
Right cheek 27 (36.5 %) 24 (32.5 %) 16 (21.7 %) 0.027
Left cheek 30 (40.5 %) 25 (338. %) 19 (25.7 %) 0.019
Tongue (dorsal side) 38 (51.4 %) 35 (47.3 %) 25 (33.8 %) 0.015
Sublingval area 26 (35.1 %) 20 (27.1 %) 9 (12.2 %) 0.001
Soft palate 24 (32.4 %) 25 (33.8 %) 12 (16.2 %) 0.008
Hard palate 18 (24.3 %) 15 (20.3 %) 9 (12.2 %) 0.002
a Differences in ulceration occurrence between day 7 and 28 after therapy was calculated using McNemar test.
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based pharmaceutical compounds. There was no significant difference in the mean age 
between the treatment groups (59.6 ± 12.6 vs 58.0 ± 10.8 years respectively; p = 0.41). In pa-
tients treated with lysozyme-based compounds, 37.8 % were male and 62.1 % were female, 
whereas in the bicarbonate-based treatment group there were 29.0 % male and 71.0 % fe-
male. There was no significant difference in the gender distribution between the two treat-
ment groups (X2 = 1.3; p = 0.3).
In patients receiving radiotherapy, a significant reduction in the number of oral ulcer-
ations was observed after 21 days of the treatment with lysozyme-based therapy. Also, in the 
lysozyme treatment group, a significant reduction in pain intensity was observed during the 
study period. However, in bicarbonate treatment group no significant reduction in the num-
ber of ulcerations nor pain intensity was observed during the period of 21 days (Table III).
In patients receiving chemotherapy, a significant reduction in the number of oral ul-
ceration and pain intensity was observed both in lysozyme and bicarbonate treatment 
group (Table IV).
Adverse treatment effects were not recorded in any subgroup of the study patients.
Patients with oral mucositis after radio- or chemotherapy have impaired immunity 
and are prone to both local and systemic infections. Oral mucositis is frequently accompa-
nied with hyposalivation, which is an additional risk factor for the secondary bacterial 
infection of mucosal ulcers (6). It is known that lysozyme exerts strong antimicrobial action 
Table III. The number of ulcerations in the whole oral cavity and pain intensity in patients on radiotherapy 
(n = 124) with lysozyme- vs. bicarbonate based treatments
Outcome Treatment of oral mucositis
7 days after the 
onset of therapy
21 days after the 
onset of therapy p-value
a
Average number of 
oral ulcerations
Lysozyme-based 
therapy 4.6 ± 3.3 1.6 ± 1.9
b < 0.001
Bicarbonate-based 
therapy 4.8 ± 4.1 4.7 ± 3.5 0.080
Pain intensity while 
eating hard food on 
PROMS scale
Lysozyme-based 
therapy 4.0 ± 3.1 2.0 ± 1.7
b < 0.001
Bicarbonate-based 
therapy 4.5 ± 3.3 3.6 ± 3.1 < 0.001
Pain intensity while 
eating soft food on 
PROMS scale
Lysozyme-based 
therapy 2.8 ± 3.0 1.0 ± 1.2
b < 0.001
Bicarbonate-based 
therapy 3.1 ± 3.3 2.8 ± 2.7 < 0.010
Pain intensity while 
speaking on PROMS 
scale
Lysozyme-based 
therapy 2.4 ± 2.8 0.9 ± 1.4
b < 0.001
Bicarbonate-based 
therapy 2.2 ± 2.6 2.0 ± 2.4 < 0.010
a p-value presented for the difference between day 7 and day 21, tested with student paired test
b Significant differences between two treatment groups (p < 0.01) tested with students t-test
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(antibacterial, antifungal and antiviral) (12), primarily in saliva and oral cavity, since it is 
the most important salivary protein along with lactoferrin and salivary peroxidase (13). 
Lysozyme also has regenerative, anti-inflammatory and immunomodulatory roles in the 
human organism (13, 14).
Our study showed that local treatment of oral mucositis caused by radiotherapy with 
lysozyme-based compounds led to more rapid healing of oral ulcerations and more pro-
nounced decrease of pain associated with eating and speaking compared to the use of bi-
carbonate-based pharmaceutical compounds. Statistical significance of the difference in 
efficacy between lysozyme- and bicarbonate-based preparations was not found in patients 
with oral mucositis after chemotherapy, but lysozyme-based compounds were clearly ef-
fective. Both lysozyme- and bicarbonate-based local preparations were well tolerated, and 
therapy-related adverse events were not recorded during the study.
Antimicrobial action of lysozyme is based on the hydrolysis of β-(1,4)-glycoside bond 
between C1 carbon of N-acetylmuramic acid (NAME) and C4 carbon atom of N-acetylglu-
cosamine (NAG) within the peptidoglycan of the cell wall (15) (16). However, it also kills 
microorganisms by the non-enzymatic mechanism. Being a polycationic compound, lyso-
zyme binds to polyanionic molecules in the cell membrane of a microorganism, teichoic 
and lipoteichoic acid, and this interaction activates autolysins which kill the microorganisms 
(15). The other proposed mechanism of action is a release of divalent cations from the 
membrane, leading to its instability and destruction. Certain studies confirmed that non-
-enzymatic mechanism of antimicrobial action is more important than enzymatic (17).
Table IV. The number of ulcerations in the whole oral cavity and pain intensity in patients on chemotherapy 
(n = 151) with lysozyme- vs. bicarbonate based treatments 
Outcome Treatment of oral mucositis
7 days after onset 
of therapy
21 days after 
onset of therapy p-value
a
Average number of 
oral ulcerations
Lysozyme-based 
therapy 2.3 ± 2.1 0.8 ± 1.6 < 0.001
Bicarbonate-based 
therapy 2.3 ± 2.0 0.9 ± 1.2 < 0.001
Pain intensity while 
eating hard food on 
PROMS scale
Lysozyme-based 
therapy 4.4 ± 2.6 0.9 ± 3.1 < 0.001
Bicarbonate-based 
therapy 3.8 ± 2.5 1.6 ± 1.6 < 0.001
Pain intensity while 
eating soft food on 
PROMS scale
Lysozyme-based 
therapy 2.1 ± 2.2 0.3 ± 0.7 < 0.001
Bicarbonate-based 
therapy 1.5 ± 1.8 0.5 ± 0.9 < 0.010
Pain intensity while 
speaking on PROMS 
scale
Lysozyme-based 
therapy 1.3 ± 2.0 0.3 ± 0.7 < 0.001
Bicarbonate-based 
therapy 0.8 ± 1.4 0.2 ± 0.6 < 0.010
a p-value presented for the difference between day 7 and day 21, tested with student paired test
702
Dž. Eminagić et al.: Efficacy and safety of local lysozyme treatment in patients with oral mucositis after chemotherapy and radio-
therapy, Acta Pharm. 69 (2019) 695–704.
 
Antimicrobial action of lysozyme was primarily designed for the action against 
Gram-positive bacteria, with a thick cell wall, but it is also active against Gram-negative 
bacteria since its penetration through the outer lipid membrane and action on the cell wall 
has been proven. Antifungal activity of lysozyme was also observed, especially against 
Candida albicans. Although the mechanism of antifungal action is not yet clarified, it is as-
sumed that lysozyme destructs glycoside bonds between peptidoglycan and structural 
proteins in the cell wall of fungi, making it unstable. A few studies have revealed a syner-
gism between lysozyme and antifungal drugs (18).
Lysozyme is one of the most important factors of non-specific immunity in oral and 
pharyngeal mucosa. It causes aggregation of bacteria and, therefore, decreases their adher-
ence to the surfaces and colonization of the oral cavity. Lysozyme also promotes adhesive 
and antimicrobial properties of immunoglobulin IgA, providing an optimal balance of 
microbial flora in the mouth. The concentration of lysozyme in the oral cavity is decreased 
in children who suffer from chronic tonsillitis and in patients with oral mucositis (19). 
Diminution of its protective role in patients on chemotherapy with oral mucositis contri-
butes to both local infection and penetration of microorganisms from mouth to blood, 
which was observed in almost 50 % of patients on chemotherapy having bacteremia (20). 
Candida albicans and Candida glabrata from the oral cavity were also found in the blood in 
patients with oral mucositis (21). 
In addition, lysozyme exerts anti-inflammatory activity which includes the stabiliza-
tion of membranes and the prevention of over-destruction of inflammatory cells along 
with the release of inflammatory mediators, inhibition of destructive enzymes during 
inflammation and prevention of over-activation of proteolytic enzymes (22). Immuno-
modu latory action of lysozyme was recognized recently (11) and confirmed by observation of 
the correlation between lysozyme concentration in oral cavity and blood levels of immuno-
globulins (12). Finally, the role of lysozyme in the regeneration of damaged mucosa was 
also established: it stimulates phagocytosis and helps with wound healing, regression of 
degenerative processes and elimination of necrotic tissue. Cells of palatal mucosa are most 
probably capable of producing lysozyme, which is absorbed by the oral mucosa and 
 increases its non-specific, natural immunity (13).
Antimicrobial, anti-inflammatory, immunomodulatory and regenerative actions of 
lysozyme could explain beneficial effects on healing of oral ulcers in patients on the radio- 
or chemotherapy that were demonstrated in our study. Although our study had certain 
limitations, like relatively small sample size, low homogeneity of the samples in regard to 
stage of neoplastic disease, cytostatic regimen or radiotherapy dose, diverse bicarbonate-
-based therapy and lacking more extensive measurement of patients’ quality of life, these 
results could be considered as preliminary and help with the planning of larger cohort 
studies and controlled clinical trials as well. 
CONCLUSIONS
In conclusion, local treatment of oral mucositis, caused by chemo- or radiotherapy, 
with lysozyme-based compounds is completely safe and clearly more effective than treat-
ment with bicarbonate-based pharmaceutical compounds. Further studies are necessary 
to determine the optimal dose and duration of treatment with lysozyme and to investigate 
its effects on systemic infections rate and mortality.
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